|Bid||2.29 x 1000|
|Ask||2.65 x 1200|
|Day's Range||2.25 - 2.39|
|52 Week Range||1.34 - 3.26|
|PE Ratio (TTM)||33.14|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.58|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MEI Pharma, Inc. Here are 5 ETFs with the largest exposure to MEIP-US. Comparing the performance and risk of MEI Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis MEI Pharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of MEI Pharma, Inc. – Array BioPharma Inc., Curis, Inc., Celgene Corporation, XOMA Corporation, Rexahn Pharmaceuticals, Inc. and Savara, Inc. (ARRY-US, CRIS-US, CELG-US, XOMA-US, RNN-US and SVRA-US) that have ... Read more (Read more...)
Quarter highlighted by dosing of first patient in pivotal Phase 3 study of pracinostat and exclusive license agreement for voruciclib Multiple key milestones lined up for year ahead SAN DIEGO , Nov. 8, ...
SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 11:00 a.m. Eastern Time from the Lotte New York Palace hotel. A live webcast of the presentation can be accessed at www.meipharma.com.
GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares rise more than 9% on the day amid huge volumes.
LONDON, UK / ACCESSWIRE / September 26, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on MEI Pharma, Inc. (NASDAQ: MEIP ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=MEIP ...
SAN DIEGO, Sept. 19, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 3:25 p.m. Eastern time from the InterContinental New York Barclay Hotel. A live webcast of the presentation can be accessed at www.meipharma.com.
Research Desk Line-up: MEI Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Teva ...
MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.
SAN DIEGO and SEATTLE, Sept. 5, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it has entered into a license agreement with Presage Biosciences, Inc. for voruciclib, a clinical-stage, oral and selective cyclin-dependent kinase (CDK) inhibitor. Under the terms of the agreement, MEI Pharma receives exclusive worldwide rights to develop, manufacture and commercialize voruciclib.
Company Begins New Fiscal Year with $53.6 Million in Cash Clinical Progress Highlighted by Initiation of Pivotal Study for Pracinostat, Emerging Response and Safety Data for ME-401 Management Team to Host ...
Live Webcasts from Boston on September 7th and New York on September 8th SAN DIEGO , Aug. 31, 2017 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development ...
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it will host a conference call with simultaneous webcast on Tuesday, September 5, 2017, at 9:00 a.m. Eastern time to discuss the Company's fiscal year 2017 results. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed AML who are unfit for intensive chemotherapy.
LUGANO, Switzerland and SAN DIEGO, Aug. 2, 2017 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that the first patient has been dosed in the pivotal Phase 3 study of the investigational agent pracinostat in combination with azacitidine in adults with newly diagnosed acute myeloid leukemia (AML) who are unfit to receive intensive induction chemotherapy. The randomized, double-blind, placebo-controlled study will enroll approximately 500 eligible patients worldwide.
BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).
Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.
Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.
Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe opioid use disorder (OUD) met its primary endpoint.
Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.
Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.